	Inlon-	7197	DA-IDC
Y	10/00	1191	RTIS USE ONLY
QUERY CONTROL FORM		- ACIONASTA	cking Number () (1992)
Application No. OO	Prepared		ek Date 8030+
Examiner-GAU UCDM	an-loi7 Date	7/2/	$(Q_{i})$
	No. of qu	Jenes //	1
	<u> </u>	SÁCKET )	D. PTO-1449
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	q. PTOL-85b
b. Applicant(s)	g. Disclaimer	I. Print Fig.	r. Abstract
c. Continuing Data	h. Microfiche Appendix	m. Searched Column n. PTO-270/328	s. Sheets/Figs
d. PCT	i. Title	o. PTO-892	t. Other
e. Domestic Priority	j. Claims Allowed	0. FTO-032	
	- 27.46 t		
SPECIFICATION	MESSAGE	1- 111 010 1	unhamun
a. Page Missing	Clares 4,9,	10 4 14 CIC I	OLM RIDIONAL
b. Text Continuity	and not re	joined per	CHINOPORT
c. Holes through Data		<i></i>	
d. Other Missing Text	(a) /	010050 1	Jaldage initial
e. Illegible Text	777)-1444	: NEast	TO LINE
f. Duplicate Text	OR/line 4	reough a	+ations.
g. Brief Description	CODIES	provided -	for reference.
	TPICE		
h. Sequence Listing	<del></del>		
i. Appendix			
j. Amendments		, N	
k. Other			
CLAIMS			
a. Claim(s) Missing		· · · · · · · · · · · · · · · · · · ·	
b. Improper Dependency	·	7.	Ghankyon
c. Duplicate Numbers			initials
d. Incorrect Numbering			n and a second
e. Index Disagrees	RESPONSE		
f. Punctuation		<u> </u>	
g. Amendments			
h. Bracketing			

initials

i. Missing Textj. Duplicate Text

k. Other



inder the Pademourk Bioduction Act of 1995, on corpora are required to respond to a cultivation of information without it contains a radii OMS control marshor

Substitute for form 1449A/PTO			Complete if Known						
		FORMATION DISCLOSURE		Continuation of 09/661.8	Continuation of 09/661,836				
(use as many sheets as necessary)									
		tabe as many empts to message yy	Filing Date	December 4, 2001	60				
•			First Named Inventor	James Ronald Lawter	145				
		· ·	Group Art Unit		Q =				
			Examiner Name						
Sheet	- 2	2 of 4	Attorney Docket Number	ORA 100/102 CON	100				
					T 80				
		OTHER ART -	- NON PATENT LITERATURE DOCUME	NTS	19				
Examiner's Initials*	Cite No.		(in CAPITAL LETTERS), title of the article ( a), serial, symposium, catalog, etc.), date, pu publisher, city and/or country where publish reduction in incidence of abha-hemolytic streptoco	agels), votume-issue number(s), hed	1-55				
	1	CARTEE, et al., "Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study," Cytobiae 7(5):471-7 (1994).							
		ICHT as at SPEE as at manufacture management and and		ak aanan aasianta afsar alambata (kaasaasa) .					
	1	leucovorin chemotherapy. J. Clin. Oncol. 13(10):2621 CUTLER & SCHUBERT, "Patient factors effecting Hei							
		leucovarin chemotherapy," J. Clin. Oncol. 13(10):2621	0-28 (1995).  **Richaster pylon eradication with triple therapy.** Ame	niceo Journal of Gastruenterology 88(4):505-5					
-		leucovarin chemotherapy, J. Can. Oncol. 13(10):2621 CUTLER & SCHUBERT, "Patient factors affecting Hei (1993).  EPSTEIN & WONG. "The efficacy of sucrallate suspe	0-28 (1995).  Geneties pylon eradication with triple therapy, ** Aims  Insign in the prevention of oral mutositis due to radia	erican Journal of Gastroenterology 88(4):505-5 stion therapy," Int. J. Rediet. Oncol. Biol. Phys.	09				
	<i>√</i>	leucovarin chemotherapy, J. Clin. Oncol. 13(10):2621  CUTLER & SCHUBERT, "Patient factors affecting Hei (1983).  EPSTEIN & WONG, "The efficacy of sucrallate suspenses 28(3):693-98 (1994).  EPSTEIN, et al., "Benzydamine hydrochloride in preven	0-28 (1995).  Dichacter pyloni eradication with triple therapy, Aimension in the prevention of oral mucositis due to radiantion and management of pain in oral mucositis asso	erican Journal of Gastreenterology 88(4):505-5 stion therapy," Int. J. Radiat. Oncol. Biol. Phys. sciated with radiation therapy," Oral Surg. Oral	09 Med: Oral				
	<i>√</i>	leucovarin chemotherapy." J. Clin. Oncol. 13(10):2621 CUTLER & SCHUBERT, "Patient factors affecting Hel (1993).  EPSTEIN & WONG, "The efficacy of sucrallate susper 28(3):693-98 (1994).  EPSTEIN, et al., "Beñrydamine hydrochloride in prever Pathol. 62(2):145-8 (1986).  EPSTEIN, et al., "Prevention of oral miscositis in radial	0-28 (1995).  Gehacter pylon eradication with triple therapy, ** Ainstruction in the prevention of oral mucositis due to radiantion and management of pain in oral mucositis assotion therapy: a controlled study with benzydamine h	erican Journal of Gastreenterology 88(4):505-5 stion therapy," Int. J. Radiat. Oncol. Biol. Phys. sciated with radiation therapy," Oral Surg. Oral	09 				
	√ √ √.	leucovarin chemotherapy, J. Cim. Oncol. 13(10):2620 CUTLER & SCHUBERT, "Patient factors affecting Hei (1993).  EPSTEIN & WONG, "The efficacy of sucraffate susper 28(3):693-98 (1994).  EPSTEIN, et al., "Benzydamine hydrochloride in prever Pathol. 62(2):145-8 (1998).  EPSTEIN, et al., "Prevention of oral mucositis in radial 16(6):1571-5 (1989).	0-28 (1995).  Dichacter pyloni eradication with triple therapy, ** Aimension in the prevention of oral mucositis due to radiantion and management of pain in oral mucositis association therapy: a controlled study with benzydamine his, Inc., pp 512-517 (1975).	erican Journal of Gastreenterology 88(4):505-5 stion therapy," Int. J. Radiat. Oncol. Biol. Phys. scieted with radiation therapy," Oral Surg. Oral sydrochlorida riusa," Int. J. Radiation Oncology I	09 Med: Oral				

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ORA 100/102 CON

Signature

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document; by the two-letter code (WIPO. Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emparor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

	Substitute 1	or form 14	49A/PTO .	Complete if Known				
•	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	Continuation of 09/661,836			
	•			Filing Date	December 4, 2001			
				First Named Inventor	James Ronald Lawter			
				Group Art Unit				
				Examiner Name				
eet <sup>.</sup>	1 3	of	4	Attorney Docket Number	ORA 100/102 CON			

		OTHER ART NON PATENT LITERATURE DOCUMENTS	<u></u>						
Examiner's Initials*	Cite No.								
	1	FOOTE, et al., "Rendomized trial of a chlorhazidina mouthwash for alleviation of radiation induced mucositis," J. Clin Oncol. 12(12):2630-33 (1994).							
		FRANCESCHI, et al., "Solitary J-pouch olcer causing pouchitis-like syndrome," Diseases of the Colon and Rectum 29(8):515-517 (1986).	. •						
	<b>√</b>	LOPRINZI, et al., "Alleviation of cytotoxic therepy induced normal tissue damage," Sen. Oncol. 22(2) Suppl. 3:95-97 (1995).							
•	√ <u>.</u> .	MITSCHER, et al., "Quinclone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids," J. Med. Chem. 21(5):485-9 (1978).							
		ROTHWELL & SPEKTOR, "Pelliation of radiation-related mucositis," Special Care in Dentistry 10(1):21-25 (1990).							
		SCHENK, et al., "Controlled local delivery of tetracycline HCl in the treatment of pertinglent mucosal hyperplasie and mucositis," Clinical Oral Implants Research 8(5):427-433 (1997).	••						
	1	SONIS, 1993b, "Oral Complications in Cencer Therepy," In: <i>Principles and Practice of Oncology</i> , De Vitta et al., eds., pp. 2385-2394 (J. B. Lippincott, Philadelphia).							
	J	Special Care in Dentistry Jan. Feb., pages 21-25 (1990).							
	j	SPIJKERVET, et al., "Chlorhexidine inactivation by saliva," <i>Oral Surg. Oral Med. Oral Pathol.</i> 59(4):444-49 (1990).							
		VERDI, et al., "A double-blind, randomized, placebo-controlled, crossover trial of pentexifylline for the prevention of chemotherapy-induced oral mucositis," Oral Surg. Oral Med. Oral Pathol. Oral Rediol. Endod. 80(1):36-42 (1995).	<del></del>						

Examinar's	\ \ \ \ \ -	 	Date	1	1/20	/22	
Signature	 MULLEY	 	Considered		1/20/	.02	·
	 • // •	 •					

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ATL1 #495286 v1

ORA 100/102 CON

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.